Lack of Pharmacodynamic Interaction of Silodosin, a Highly Selective α1a-Adrenoceptor Antagonist, With the Phosphodiesterase-5 Inhibitors Sildenafil and Tadalafil in Healthy Men

Urology

Volumn 75, Issue 3, 2010, Pages 520-525

  MacDiarmid, Scott A ^a   Hill, Lawrence A ^b   Volinn, Weining ^b   Hoel, Gary ^b  

^a Bladder Control and Pelvic Pain Center   (United States)

^b Watson Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SILDENAFIL; SILODOSIN; TADALAFIL;

ADULT; AGED; ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPEPSIA; HEART RATE; HUMAN; INGUINAL PAIN; MALAISE; MALE; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; RETROGRADE EJACULATION; SCROTAL PAIN; SINGLE DRUG DOSE; SINUS HEADACHE; STANDING; STOMACH DISCOMFORT; SYSTOLIC BLOOD PRESSURE; TIME; VOMITING;

AGED; CARBOLINES; CROSS-OVER STUDIES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DRUG INTERACTIONS; HUMANS; INDOLES; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; POSTURE; PURINES; RECEPTORS, ADRENERGIC, ALPHA-1; SULFONES;

EID: 77649339569     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.10.042     Document Type: Article

References (15)

1. Wei J.T., Calhoun E.A., and Jacobsen S.J. Benign prostatic hyperplasia. In: Litwin M.S., and Saigal C.S. (Eds). Urologic Diseases in America (2007), National Kidney and Urologic Diseases Information Clearinghouse, Bethesda, MD. http://kidney.niddk.nih.gov/statistics/uda/ NIH publication: 07-5512:43-67. Available at: (updated February 2007). Accessed August 28, 2008
2. Seftel A.D., Rosen R.C., Rosenberg M.T., et al. Benign prostatic hyperplasia evaluation, treatment and association with sexual dysfunction: practice patterns according to physician specialty. Int J Clin Pract 62 (2008) 614-622
3. Cambio A.J., and Evans C.P. Outcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH). Ther Clin Risk Manag 3 (2007) 181-196
4. Schwinn D.A., and Roehrborn C.G. Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol 15 (2008) 193-199
5. Lepor H. The evolution of alpha-blockers for the treatment of benign prostatic hyperplasia. Rev Urol 8 suppl 4 (2006) S3-S9
6. Kloner R.A. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation 110 (2004) 3149-3155
7. Reffelmann T., and Kloner R.A. Sexual function in hypertensive patients receiving treatment. Vasc Health Risk Manag 2 (2006) 447-455
8. Shibata K., Foglar R., Horie K., et al. KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues. Mol Pharmacol 48 (1995) 250-258
9. Yamada S., Okura T., and Kimura R. In vivo demonstration of alpha(1A)-adrenoceptor subtype selectivity of KMD-3213 in rat tissues. J Pharmacol Exp Ther 296 (2001) 160-167
10. Yamagishi R., Akiyama K., Nakamura S., et al. Effect of KMD-3213, an alpha 1a-adrenoceptor-selective antagonist, on the contractions of rabbit prostate and rabbit and rat aorta. Eur J Pharmacol 315 (1996) 73-79
11. Murata S., Taniguchi T., Takahashi M., et al. Tissue selectivity of KMD-3213, an alpha(1)-adrenoreceptor antagonist, in human prostate and vasculature. J Urol 164 (2000) 578-583
12. 1a-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol 181 (2009) 2634-2640
13. Moore R.A., Derry S., and McQuay J. Indirect comparison of interventions using published randomized trials: systematic review of PDE-5 inhibitors for erectile dysfunction. BMC Urol 5 (2005) 18
14. Auerbach S.M., Gittelman M., Mazzu A., et al. Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia. Urology 64 (2004) 998-1003
15. Kloner R.A., Jackson G., Emmick J.T., et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 172 (2004) 1935-1940